Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

British Journal of Cancer, Published online: 24 February 2024; doi:10.1038/s41416-024-02604-yFluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

Source: British Journal of Cancer - February 24, 2024 Category: Cancer & Oncology Authors: C. S. Karapetis H. Liu M. J. Sorich L. D. Pederson E. Van Cutsem T. Maughan J. Y. Douillard C. J. O ’Callaghan D. Jonker C. Bokemeyer A. Sobrero C. Cremolini B. Chibaudel J. Zalcberg R. Adams M. Buyse M. Peeters T. Yoshino A. de Gramont Q. Shi Source Type: research